XML 66 R56.htm IDEA: XBRL DOCUMENT v3.23.3
Transactions - Narrative (Details) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Jan. 20, 2023
Aug. 01, 2022
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Business Acquisition [Line Items]              
Cash         $ 388,246,000 $ 245,021,000  
Discrete tax benefit     $ 5,550,000 $ 45,516,000 74,709,000 44,498,000  
Revenue [1]     511,015,000 352,585,000 1,407,841,000 969,581,000  
Net income (loss) attributable to common shareholders of Evolent Health, Inc.     $ (25,324,000) $ 2,123,000 $ (79,629,000) $ (7,815,000)  
Corporate trade name              
Business Acquisition [Line Items]              
Estimated useful life     1 year   1 year    
NIA              
Business Acquisition [Line Items]              
Total consideration $ 715,694,000            
Cash 387,823,000            
Fair value of Class A common stock issued 261,271,000            
Contingent consideration arrangements (up to) $ 150,000,000            
Percentage of contingent consideration allowed to be paid in equity interest (up to) 50.00%            
Contingent consideration $ 66,600,000            
Goodwill, expected tax deductible amount $ 0            
Discrete tax benefit         $ 56,100,000    
Revenue         167,500,000    
Net income (loss) attributable to common shareholders of Evolent Health, Inc.         $ 1,400,000    
NIA | Common Class A              
Business Acquisition [Line Items]              
Equity interest issued or issuable, number of shares (in shares) 8,474,576            
NIA | Customer relationships              
Business Acquisition [Line Items]              
Estimated useful life 15 years            
NIA | Technology              
Business Acquisition [Line Items]              
Estimated useful life 5 years            
NIA | Corporate trade name              
Business Acquisition [Line Items]              
Estimated useful life 2 years            
IPG              
Business Acquisition [Line Items]              
Total consideration   $ 461,663,000          
Cash   $ 256,488,000          
Equity interest issued or issuable, number of shares (in shares)   3,700,000          
Fair value of Class A common stock issued   $ 130,175,000          
Contingent consideration arrangements (up to)   87,000,000          
Contingent consideration   75,000,000          
Goodwill, expected tax deductible amount   $ 0          
Discrete tax benefit             $ 46,800,000
Voting interests acquired   100.00%          
IPG | Customer relationships              
Business Acquisition [Line Items]              
Estimated useful life   20 years          
IPG | Technology              
Business Acquisition [Line Items]              
Estimated useful life   5 years          
IPG | Corporate trade name              
Business Acquisition [Line Items]              
Estimated useful life   15 years          
[1] See Note 18 for amounts attributable to unconsolidated related parties included in these line items.